이상반응 보고
| VAERS ID | 2422892 |
|---|---|
| 성별 | 여성 |
| 나이 | 37세 |
| 주 코드 | TX |
| 제약회사 | PFIZER\BIONTECH |
| 로트 번호 | ER8733 |
| 예방접종 횟수 | 2 |
| 접종일 | 2021-03-28 |
| 발병일 | 2022-08-26 |
| 상태 | 입원 사망 |
증상
- 집중 치료(Intensive care)
- 통증(Pain)
- 상태가 악화됨(Condition aggravated)
- 흉부 엑스레이 이상(Chest X-ray abnormal)
- 정신 상태 변화(Mental status changes)
- SARS-CoV-2 테스트 양성(SARS-CoV-2 test positive)
- 고혈당(Hyperglycaemia)
- 폐 장애(Lung disorder)
- 헤마토크릿 감소(Haematocrit decreased)
- 혈소판 감소증(Thrombocytopenia)
- 헤모글로빈 감소(Haemoglobin decreased)
- 혈중 알칼리성 인산분해효소 증가(Blood alkaline phosphatase increased)
- 혈액 빌리루빈 증가(Blood bilirubin increased)
- 기관 삽관(Endotracheal intubation)
- 급성 신장 손상(Acute kidney injury)
- 코로나19 폐렴(COVID-19 pneumonia)
- 호흡부전(Respiratory failure)
- 죽음(Death)
- 저산소증(Hypoxia)
- 아스파르테이트 아미노전이효소 증가(Aspartate aminotransferase increased)
- 심장 마비(Cardiac arrest)
- 백혈구 증가증(Leukocytosis)
- 전반적인 신체 건강 악화(General physical health deterioration)
- 태아 사망(Foetal death)
- 급성 호흡 부전(Acute respiratory failure)
- 간질성 폐질환(Interstitial lung disease)
- 임신 전 산모 노출(Maternal exposure before pregnancy)
- 급성 호흡기 장애 증후군(Acute respiratory distress syndrome)
- 무맥동 전기 활동(Pulseless electrical activity)
- 플라즈마 교환(Plasmapheresis)
- 태반의 조기 분리(Premature separation of placenta)
- 폐렴 흡인(Pneumonia aspiration)
- 파종 성 혈관 내 응고(Disseminated intravascular coagulation)
- 다발성 장기 기능 장애 증후군(Multiple organ dysfunction syndrome)
- 위기를 동반한 겸상적혈구빈혈(Sickle cell anaemia with crisis)
- 제왕 절개(Caesarean section)
- 폐 보조 장치 치료(Lung assist device therapy)
- 간 생검(Biopsy liver)
- 과아미노산혈증(Hypertransaminasaemia)
- 적혈구 수혈(Red blood cell transfusion)
이환 중 질병
지병
Sickle cells anemia, protein s deficiency, 37 weeks gestation, heart murmur
기타 의료
enoxaparin, folic acid, hydrocodone-acetaminophen, ibuprofen, Vitamin D3
이전 예방접종
알레르기
NKDA
임상 검사
covid + 8/13/22 ;This sample was analyzed using the Cepheid GeneXpert platform using PCR or equivalent Nucleic Acid Amplification (NAA) technology.
증상 상세
Pfizer-BioNTech COVID-19 Vaccine EUA Rec'd Pfizer-BioNTech COVID Vaccine on 3/3/21 and 3/28/21.
Admitted 8/12/22 @ 37wk gestation for tx of sickle cell pain crisis w/IVF and pain relief.
ED labs - Tbili 3.
2, Alk phos 172, AST 80, Hgb 11.
2, Hematocrit 31.
1, SARS-CoV-2 detected, CXR revealing Increased interstitial markings bilaterally.
8/13/22 clinical course c/b nonreassuring FHR strip, acute mental status changese and hypoxia.
Underwent Cesarean 2/2 IUFD, DIC/abruption noted.
Rec'd 4u pRBC, u1 FFP, 1u Plts.
Transferred to ICU intubated.
POD #1 c/b resp failure & liver shock.
Postop course c/b worsening resp status w/sickle cell crisis, acute hypox resp fail.
severe Covid PNA, asp PNA, AKI, leukocytosis, transaminitis, reactive hyperglycemia and thrombocytopenia.
Pulmonary status cont to decline; VV ecmo started w/improvement in sats.
Severe ARDS w/refractory hypoxia present; trach place 8/23/22.
8/25/22 PEA arrest c/b multiorgan failure.
On 8/25/22 overall condition determined to be terminal and irreversible.
Status changed to DNAR and transitioned to comfort care.
Tx'd w/decadron, , zosyn,cefepime, clindamycin, azithroycin, flagyl and remdesivir.
Expired 8/26/22.